Dr. Kathy Han
Inclusion Criteria:
- Patients must have had surgery consisting of hysterectomy and bilateral
salpingo-oophorectomy. Lymph node dissection can be performed as per institutional
standards. There must be no macroscopic residual disease after surgery.
- Patients must have histologically confirmed Stage I to III endometrial carcinoma
which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma
or mixed.
- Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral
load within 6 months are eligible for this trial.
- Patients' age must be ≥ 18 years.
- Patient consent must be appropriately obtained in accordance with applicable local
and regulatory requirements.
- Patient is able (i.e. sufficiently fluent) and willing to complete the
patient-reported outcomes (PRO) questionnaires in either English, French or a
validated language
- Patients must be accessible for treatment and follow-up. Patients enrolled on this
trial must be treated and followed at the participating centre
- Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral
salpingo-oophorectomy
Exclusion Criteria:
- Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis.
- Prior pelvic radiation.
- Patients with a history of other malignancies, except: adequately treated
non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other
solid tumours curatively treated with no evidence of disease for ≥ 5 years.
- Clinical evidence of distant metastasis as determined by pre-surgical or
post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT
scan) (